Johnson v. Scimed, Inc.

92 F. Supp. 2d 587, 2000 WL 381554
CourtDistrict Court, W.D. Louisiana
DecidedMarch 15, 2000
DocketCIV. A. 99-2352
StatusPublished
Cited by3 cases

This text of 92 F. Supp. 2d 587 (Johnson v. Scimed, Inc.) is published on Counsel Stack Legal Research, covering District Court, W.D. Louisiana primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Johnson v. Scimed, Inc., 92 F. Supp. 2d 587, 2000 WL 381554 (W.D. La. 2000).

Opinion

MEMORANDUM RULING

PAYNE, United States Magistrate Judge.

Introduction

Doris Johnson died while being treated at Willis-Knighton Medical Center by Drs. Phillip Rozeman and Anil Chhabra. Mrs. Johnson’s surviving spouse and two sons filed a medical malpractice review panel petition against the medical center and both physicians. The next day, the John-sons filed a products liability lawsuit in state court against Scimed, Inc., the manufacturer of stents which were used in the treatment of Mrs. Johnson. The plaintiffs also named the medical center, Dr. Roze-man and Dr. Chhabra as defendants in the state court suit, even though Louisiana law requires the completion of review panel proceedings before a civil action for malpractice may be commenced against a qualified health care provider.

Scimed removed the case to this court, citing diversity jurisdiction. See 28 U.S.C. §§ 1332 & 1441(a). The amount in controversy requirement is easily satisfied, and all parties agree that the plaintiffs and Scimed are citizens of different states. There is however, no dispute that two of the plaintiffs as well the medical center, Dr. Chhabra and Dr. Rozeman are all citizens of Louisiana, which would appear to destroy the complete diversity that is required by §1332. 1 Scimed nonetheless removed the case, asserting that the citizenship of the Louisiana health care providers could be ignored because they were “fraudulently joined.” Scimed based the fraudulent joinder plea on Louisiana law that deems premature any malpractice action against the health care providers until completion of the review panel proceedings. The plaintiffs have put the fraudulent joinder claim to the test by filing a Motion to Remand (Doc.9) that is now before the court. For reasons that follow, the court finds that the medical malpractice defendants were not fraudulently joined. The Motion to Remand will be granted.

Effect of Unserved Defendants

Two preliminary matters are raised by the parties and must be resolved before turning to the principal issue. First, at the time of removal, the Louisiana *589 defendants had not been served. Scimed cited this fact in its notice of removal as justification for the Louisiana defendants not joining in the notice of removal. Scimed is correct that only those defendants who are properly joined and served must join in the notice of removal. See Getty Oil Corp. v. Insurance Co. of North America, 841 F.2d 1254, 1262 (5th Cir.1988). 2

The second issue is whether diversity jurisdiction is affected by the citizenship of the unserved Louisiana defendants. The law is clear that “whenever federal jurisdiction in a removal case depends upon complete diversity, the existence of diversity is determined from the fact of citizenship of the parties named and not from the fact of service.” New York Life Insurance Co. v. Deshotel, 142 F.3d 873, 883 (5th Cir.1998). Accordingly, the Louisiana malpractice defendants destroy diversity unless they were fraudulently joined.

Fraudulent Joinder Issues

This lawsuit presents a set of jurisdictional facts that is often faced by this court in same or similar situations. A Louisiana patient or her survivors file a products liability action against an out-of-state manufacturer of a medical device. The physician^) who implanted the device and the hospital where the procedure was performed, usually Louisiana citizens, are also accused of malpractice. Louisiana law provides in La.R.S. 40:1229.47(B)(l)(a)(i) that:

No action against a health care provider covered by this Part, or his insurer, may be commenced in any court of this state before the claimant’s proposed complaint has been presented to a medical review panel established pursuant to this Section and an opinion is rendered by the panel. By agreement of both parties, the use of the medical review panel may be waived.

A pending review panel action suspends prescription on the medical malpractice claims. Section 1299.47(A)(2)(a). Filing a request for panel-review of a claim against a health care provider also suspends the running of prescription against all joint and solidary tortfeasors. Id. But if it is ultimately determined that the health care provider is not liable, then there may not have been a suspension, and claims against persons once thought to be joint tortfea-sors could be prescribed. Spott v. Otis Elevator Co., 601 So.2d 1355, 1359-61 (La.1992). Because of this and other concerns, the plaintiffs’ counsel often take the cautious approach of not awaiting the outcome of the panel proceeding before commencing a timely civil action against the manufacturer of the medical device.

When the out-of-state manufacturer is the sole defendant in a civil action filed by a Louisiana plaintiff, the case is often removed and there is seldom any doubt that the court has subject matter jurisdiction based upon diversity. What inevitably happens in such cases is that the plaintiffs, and sometimes the defendant-manufacturer too, request that the court delay setting a federal trial date because it is anticipated that as soon as the medical review panel proceedings are completed the plaintiffs will file a motion to amend the complaint to add the non-diverse physicians and hospital. The court has discretion as to whether to permit that post-removal amendment, but leave is usually granted because the relevant factors point in that direction. See Hensgens v. Deere & Co., 833 F.2d 1179 (5th Cir.1987) (setting forth factors that guide that discretion). See also Cobb v. Delta Exports, Inc., 186 F.3d 675 (5th Cir.1999) (reaffirming Hensgens). Among the principal reasons that the court permits joinder in that situation is the large and unnecessary burden on the plaintiffs and the state-federal judicial system of requiring separate trials in federal and state court on issues that are either identical or closely intertwined. Matters are even more unnecessarily complicated if the federal court forces the plaintiffs to file *590 separate actions and the defendant in either action files a third-party demand against the defendant in the other case. That situation, which is not unusual, results in the plaintiffs and the defendants bearing the expense of separate litigation on the same issues and risks inconsistent results.

This case presents a slightly different situation; the plaintiffs immediately sued both the device manufacturer and the health care providers in the state court action without awaiting completion of the panel proceedings. The plaintiffs undoubtedly knew that the claims against the health care providers would be subject to dismissal for prematurity if the health care providers filed a dilatory exception on that grounds.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Prather v. Utiliquest, L.L.C.
313 F. Supp. 2d 666 (S.D. Texas, 2004)
Englande v. SMITHKLINE
206 F. Supp. 2d 815 (E.D. Louisiana, 2002)
Jamison v. Kerr-McGee Corp.
151 F. Supp. 2d 742 (S.D. Mississippi, 2001)

Cite This Page — Counsel Stack

Bluebook (online)
92 F. Supp. 2d 587, 2000 WL 381554, Counsel Stack Legal Research, https://law.counselstack.com/opinion/johnson-v-scimed-inc-lawd-2000.